Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMedOpen access

Autologous adipose tissue transfer in progressive hemifacial atrophy: From simple volume to regenerative cell therapy.

Foba ML., Mégevand V., Scampa M., Teuw EHD., Quinodoz P., Sankale AA.

Narrative Review on Immune Modulation, Autoimmune Research, published in JPRAS Open (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
JPRAS Open (2025)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
40584563
PMCID
PMC12206044
DOI
10.1016/j.jpra.2025.05.003

Abstract (original English)

Background Progressive hemifacial atrophy (PHA), including en-coup-de-sabre morphea and Parry-Romberg syndrome, is a rare condition characterized by unilateral atrophy of facial tissues. The etiology of PHA remains unclear, though it is generally considered to be an autoimmune disease. Current treatment approaches typically involve systemic immunosuppression to stabilize the disease, followed by reconstructive surgery to restore facial symmetry, ranging from complex flap reconstruction to autologous fat transfer (AFT) and allogenic fillers. Recent evidence supports AFT not only as a volumetric filler but also for its immunomodulatory and angiogenic properties, making it a promising supplement or even alternative to systemic immunosuppressive therapy. Methods We present four cases of PHA treated with AFT in Dakar, Senegal, and Geneva, Switzerland. A comprehensive review of evidence supporting AFT as a cellular therapy in patients with PHA was performed discussing its potential as an effective stand-alone therapeutic option. Results There is growing evidence that AFT has regenerative effects in fibrotic autoimmune disease, including scleroderma and PHA. This is in line with our results showing not only improved facial contours and a restoration of symmetrical fullness but also improved overall tissue quality after AFT. Conclusion We advocate AFT to be a safe and reliable therapy

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research